Eli Lilly and Company will not attempt a large-scale merger similar to the ones currently in the big pharma news; instead, the company says it will continue to implement its diversified drug development model, with a healthy dose of partnerships adding to in-house R&D. One of the goals of the company is to become the fastest growing pharmaceutical company operating in China. More details...

Stock Symbol: (NYSE: LLY)